Last updated on February 2018
Effect and Efficacy of Xpedition /Alpine Everolimus-eluting Stent for Coronary Atherosclerosis
Brief description of study
The objectives of this study are
- To establish a prospective registry of the whole patients who received percutaneous coronary intervention with Xience Xpedition/Alpine stent
- To evaulate the long-term efficacy and safety of coronary stenting with the Xience Xpedition/Alpine stent
- To compare the long-term efficacy and safety of coronary stenting between the Xience Xpedition/Alpine stent and other contemporary drug-eluting stents which had established their own registry
Detailed Study Description
Secondary endpoints of this study are
Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI
Target vessl failure
Composite rate of cardiac death and any MI, 3 years
Composite rate of all death and any MI
Composite rate of all death, any MI, and any repeat revascularization
Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy
Clinical Study Identifier: NCT02845804